Skip to main content

Advertisement

We're creating a new version of this page. See preview

Volume 3 Supplement 1

ESICM LIVES 2015

  • Poster presentation
  • Open Access

Levosimendan use in critical care - a case series

  • 1 and
  • 1
Intensive Care Medicine Experimental20153 (Suppl 1) :A540

https://doi.org/10.1186/2197-425X-3-S1-A540

  • Published:

Keywords

  • Intensive Care Unit
  • Acute Myocardial Infarction
  • Acute Myocardial Infarction
  • Aortic Stenosis
  • Levosimendan

Introduction

Levosimendan is a calcium sensitiser that enhances myocardial contractility without increasing myocardial oxygen consumption or adversely affecting diastolic function. Whilst theoretically attractive, lack of outcome data in critically ill patients means that it is not yet established in intensive care practice. We have been using levosimendan on our Intensive Care Unit (ICU) for more than 6 years and the data presented here represents one of the largest case series on the use of levosimendan in this setting.

Objectives

To retrospectively analyse the cases of patients on a general ICU who were treated with levosimendan.

Methods

Our electronic patient record was used to identify patients who had been treated with levosimendan between 2009 and 2014. Patients' notes were analysed for demographic and clinical data. Subgroups for each answer were predefined and the best fit answer was decided by the investigator. A second search (2011-2013) was used to identify 2 matched control populations: acute myocardial infarction (AMI) and pneumonia. A chi-squared test was used to see if there was a difference in ICU outcomes between the matched controls and those treated with levosimendan.

Results

Over the 5 year period levosimendan was used in 90 patient cases. Exactly half the patients died in the ICU (Table 1).

Table 1

 

ICU survivors (Mean (range))

ICU non-survivors (Mean (range))

No. patients

45

45

Age

61 (28-83)

71 (17-89)

APACHE-2 score

21 (8-36)

20 (0-37)

72% of patients had cardiac monitoring to aid diagnosis and response to treatment; 28% were treated on clinical grounds alone.

81% of patients were mechanically ventilated and 77% were already on vasoactive infusions.

3 patients were documented to have aortic stenosis, a contraindication to levosimendan.

33% of patients had a >20% fall in systolic blood pressure associated with the use of levosimendan. 6% had a new arrhythmia.

For patients with cardiac failure associated with AMI there was a statistically significant difference between the ICU mortality of those treated with or without levosimendan, favouring levosimendan. There were insufficient data to draw conclusions about those with pneumonia (Table 3).
Table 2

Indications for the use of levosimendan.

 

No. cases

Indication

ICU survivors

ICU non-survivors

Ischaemic heart failure

26

25

Sepsis induced cardiomyopathy

10

14

Acutely decompensated chronic heart failure

6

5

Right heart failure

1

3

Table 3

 

Control

Levosimendan

p-value

Pneumonia

   

APACHE-2 score

23.7

23.9

 

ICU mortality

41/168 = 24%

5/9 = 56%

N/A

AMI

   

APACHE-2 score

16.7

19.8

 

ICU mortality

47/78 = 60%

25/51 = 49%

p = 0.0247

Conclusions

In this case series, the most common indication for levosimendan use was heart failure secondary to AMI. We observed an ICU survival benefit in using levosimendan in this group of patients. This finding is supported by the RUSSLAN study that showed a short-term survival benefit to using levosimendan in this patient group [1]. Whilst there is, to date, no evidence for a long-term mortality benefit in patients with AMI induced cardiac failure, there is supporting evidence for patients with acute decompensation of their chronic cardiac insufficiency [2].

Authors’ Affiliations

(1)
Royal Devon and Exeter Hospital, Intensive Care Medicine, Exeter, United Kingdom

References

  1. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002, 23 (18): 1422-1432. 10.1053/euhj.2001.3158.PubMedView ArticleGoogle Scholar
  2. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure: a randomised double-blind trial. Lancet. 2002, 360 (9328): 196-202. 10.1016/S0140-6736(02)09455-2.PubMedView ArticleGoogle Scholar

Copyright

© Gibson et al.; 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement